Placental growth factor promotes metastases of ovarian cancer through MiR-543-regulated MMP7

Cellular Physiology and Biochemistry

Volumn 37, Issue 3, 2015, Pages 1104-1112

  Song, Ning ^a   Liu, Hao ^a   Ma, Xiaoxin ^a   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Matrix metalloproteinase 7 (MMP7); MiR 543; Ovarian cancer (OC); Placental growth factor (PLGF)

Indexed keywords

MATRILYSIN; MESSENGER RNA; MICRORNA; MICRORNA 543; PLACENTAL GROWTH FACTOR; TUMOR PROMOTER; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN543 MICRORNA, HUMAN; MMP7 PROTEIN, HUMAN; PLACENTA PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OVARIAN CANCER CELL LINE; OVARIAN TISSUE; OVARY METASTASIS; PRIORITY JOURNAL; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ADULT; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 7; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PREGNANCY PROTEINS;

EID: 84942242855     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430235     Document Type: Article

References (45)

1. Zhang S, Hou X, Zi S., Wang Y, Chen L, Kong B: Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in chinese patients. Cell Physiol Biochem 2013; 31:525-531.
2. Sun N, Zhang Q, Xu C., Zhao Q, Ma Y, Lu X., Wang L, Li W: Molecular regulation of ovarian cancer cell invasion. Tumour Biol 2014; 35:11359-11366.
3. Chen Q, Qin R, Fang Y., Li H: Berberine sensitizes human ovarian cancer cells to cisplatin through mir-93/pten/akt signaling pathway. Cell Physiol Biochem 2015; 36:956-965.
4. Ge T, Yin M, Yang M., Liu T, Lou G: Microrna-302b suppresses human epithelial ovarian cancer cell growth by targeting runx1. Cell Physiol Biochem 2014; 34:2209-2220.
5. He QZ, Luo XZ, Wang K, Zhou Q., Ao H, Yang Y, Li S.X., Li Y., Zhu HT, Duan T: Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem 2014; 33:173-184.
6. Jeong GO, Shin SH, Seo E.J., Kwon YW, Heo SC, Kim KH, Yoon M.S., Suh DS, Kim JH: Taz mediates lysophosphatidic acid-induced migration and proliferation of epithelial ovarian cancer cells. Cell Physiol Biochem 2013; 32:253-263.
7. Teng Y, Zhao L, Zhang Y., Chen W, Li X: Id-1, a protein repressed by mir-29b, facilitates the tgfbeta1-induced epithelial-mesenchymal transition in human ovarian cancer cells. Cell Physiol Biochem 2014; 33:717-730.
8. Smolarz B, Szyllo K, Romanowicz-Makowska H, Niewiadomski M., Kozlowska E, Kulig A: Pcr analysis of matrix metalloproteinase 3 (mmp-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol 2003; 54:233-238.
9. Szyllo K, Smolarz B, Romanowicz-Makowska H, Niewiadomski M., Kozlowska E, Kulig A: The promoter polymorphism of the matrix metalloproteinase 3 (mmp-3) gene in women with ovarian cancer. J Exp Clin Cancer Res 2002; 21:357-361.
10. Roomi MW, Monterrey JC, Kalinovsky T, Rath M., Niedzwiecki A: In vitro modulation of mmp-2 and mmp-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. Oncol Rep 2010; 23:605-614.
11. Brun JL, Cortez A, Lesieur B., Uzan S, Rouzier R, Darai E: Expression of mmp-2, -7, -9, mt1-mmp and timp-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep 2012; 27:1049-1057.
12. Kenny HA, Kaur S, Coussens L.M., Lengyel E: The initial steps of ovarian cancer cell metastasis are mediated by mmp-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008; 118:1367-1379.
13. Kenny HA, Lengyel E: Mmp-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle 2009; 8:683-688.
14. Che YL, Luo SJ, Li G, Cheng M., Gao YM, Li XM, Dai JM, He H, Wang J., Peng HJ, Zhang Y, Li WY, Wang H, Liu B., Linghu H: The c3g/rap1 pathway promotes secretion of mmp-2 and mmp-9 and is involved in serous ovarian cancer metastasis. Cancer Lett 2015; 359:241-249.
15. Tanimoto H, Underwood LJ, Shigemasa K, Parmley T.H., Wang Y., Yan Y, Clarke J, O'Brien TJ: The matrix metalloprotease pump-1 (mmp-7, matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999; 20:88-98.
16. Zhao H, Yang Z, Wang X., Zhang X, Wang M, Wang Y., Mei Q, Wang Z: Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of e-cadherin. Exp Mol Med 2012; 44:633-641.
17. Chang MC, Chen CA, Chen P.J., Chiang YC, Chen YL, Mao TL, Lin H.W., Lin Chiang WH, Cheng WF: Mesothelin enhances invasion of ovarian cancer by inducing mmp-7 through mapk/erk and jnk pathways. Biochem J 2012; 442:293-302.
18. Wang FQ, So J, Reierstad S., Fishman DA: Matrilysin (mmp-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 2005; 114:19-31.
19. Zhou X, Qi Y: Plgf inhibition impairs metastasis of larynx carcinoma through mmp3 downregulation. Tumour Biol 2014; 35:9381-9386.
20. Mao D, Zhang Y, Lu H., Zhang H: Molecular basis underlying inhibition of metastasis of gastric cancer by anti-vegfa treatment. Tumour Biol 2014; 35:8217-8223.
21. Liu G, Xu S, Jiao F., Ren T, Li Q: Vascular endothelial growth factor b coordinates metastasis of non-small cell lung cancer. Tumour Biol 2015; 36:2185-2191.
22. Gong J, Zhu S, Zhang Y., Wang J: Interplay of vegfa and mmp2 regulates invasion of glioblastoma. Tumour Biol 2014; 35:11879-11885.
23. Ding H, Zhu Y, Chu T., Wang S: Epidermal growth factor induces foxo1 nuclear exclusion to activate mmp7-mediated metastasis of larynx carcinoma. Tumour Biol 2014; 35:9987-9992.
24. Chen Y, Jiang T, Mao A., Xu J: Esophageal cancer stem cells express plgf to increase cancer invasion through mmp9 activation. Tumour Biol 2014; 35:12749-12755.
25. Chen B, Zhang C, Dong P., Guo Y, Mu N: Molecular regulation of cervical cancer growth and invasion by vegfa. Tumour Biol 2014; 35:11587-11593.
26. Bu J, Bu X, Liu B., Chen F, Chen P: Inhibition of metastasis of oral squamous cell carcinoma by anti-plgf treatment. Tumour Biol 2015; 36:2695-2701.
27. Ferrara N: Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009; 29:789-791.
28. Xiao X, Prasadan K, Guo P., El-Gohary Y, Fischbach S, Wiersch J., Gaffar I, Shiota C, Gittes GK: Pancreatic duct cells as a source of vegf in mice. Diabetologia 2014; 57:991-1000.
29. Xiao X, Guo P, Chen Z., El-Gohary Y, Wiersch J, Gaffar I., Prasadan K, Shiota C, Gittes GK: Hypoglycemia reduces vascular endothelial growth factor a production by pancreatic beta cells as a regulator of beta cell mass. J Biol Chem 2013; 288:8636-8646.
30. Ferrara N, Gerber HP, LeCouter J: The biology of vegf and its receptors. Nat Med 2003; 9:669-676.
31. Fischer C, Jonckx B, Mazzone M., Zacchigna S, Loges S, Pattarini L., Chorianopoulos E, Liesenborghs L, Koch M., De Mol M, Autiero M, Wyns S., Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P: Anti-plgf inhibits growth of vegf(r)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131:463-475.
32. Autiero M, Waltenberger J, Communi D., Kranz A, Moons L, Lambrechts D., Kroll J, Plaisance S, De Mol M, Bono F, Kliche S., Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M., Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Shibuya M, Collen D, Conway EM, Carmeliet P: Role of plgf in the intra- and intermolecular cross talk between the vegf receptors flt1 and flk1. Nat Med 2003; 9:936-943.
33. Huo X, Li Y, Jiang Y., Sun X, Gu L, Guo W., Sun D: Inhibition of ocular neovascularization by co-inhibition of vegf-a and plgf. Cell Physiol Biochem 2015; 35:1787-1796.
34. Jiang H, Wu X, Wang H., Huang C, Zhang L: Combined anti-plgf and anti-endostatin treatments inhibit ocular hemangiomas. Cell Physiol Biochem 2015; 36:930-936.
35. Zhang J, Wang S, Lu L., Wei G: Mir99a modulates mmp7 and mmp13 to regulate invasiveness of kaposi's sarcoma. Tumour Biol 2014; 35:12567-12573.
36. Wang Q, Cai J, Wang J., Xiong C, Zhao J: Mir-143 inhibits egfr-signaling-dependent osteosarcoma invasion. Tumour Biol 2014; 35:12743-12748.
37. Wang F, Xiao W, Sun J., Han D, Zhu Y: Mirna-181c inhibits egfr-signaling-dependent mmp9 activation via suppressing akt phosphorylation in glioblastoma. Tumour Biol 2014; 35:8653-8658.
38. Liu G, Jiang C, Li D., Wang R, Wang W: Mirna-34a inhibits egfr-signaling-dependent mmp7 activation in gastric cancer. Tumour Biol 2014; 35:9801-9806.
39. Song W, Li Q, Wang L., Huang W, Wang L: Foxo1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Sci Rep 2015; 5:10081.
40. Song W, Li Q, Wang L., Wang L: Modulation of foxo1 expression by mir-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem 2015; 35:184-190.
41. Ji D, Li B, Shao Q., Li F, Li Z, Chen G: Mir-22 suppresses bmp7 in the development of cirrhosis. Cell Physiol Biochem 2015; 36:1026-1036.
42. Chang Y, Zhao Y, Gu W., Cao Y, Wang S, Pang J., Shi Y: Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through mir-148a. Cell Physiol Biochem 2015; 36:1186-1196.
43. Bing L, Hong C, Li-Xin S, Wei G: Microrna-543 suppresses endometrial cancer oncogenicity via targeting fak and twist1 expression. Arch Gynecol Obstet 2014; 290:533-541.
44. Li FQ, Xu B, Wu Y.J., Yang ZL, Qian JJ: Differential microrna expression in signet-ring cell carcinoma compared with tubular adenocarcinoma of human gastric cancer. Genet Mol Res 2015; 14:739-747.
45. Tao WY, Liang XS, Liu Y, Wang C.Y., Pang D: Decrease of let-7f in low-dose metronomic paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer. Int J Biol Sci 2015; 11:48-58.